CN110025608A - 降低心血管疾病风险的方法 - Google Patents

降低心血管疾病风险的方法 Download PDF

Info

Publication number
CN110025608A
CN110025608A CN201910123564.7A CN201910123564A CN110025608A CN 110025608 A CN110025608 A CN 110025608A CN 201910123564 A CN201910123564 A CN 201910123564A CN 110025608 A CN110025608 A CN 110025608A
Authority
CN
China
Prior art keywords
patient
ldl
compound
formula
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910123564.7A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·L·比斯盖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yao Shi Treatment Co
Original Assignee
Yao Shi Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yao Shi Treatment Co filed Critical Yao Shi Treatment Co
Publication of CN110025608A publication Critical patent/CN110025608A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910123564.7A 2012-01-06 2013-01-04 降低心血管疾病风险的方法 Pending CN110025608A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
US61/584,002 2012-01-06
CN201380004642.2A CN104136023A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380004642.2A Division CN104136023A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Publications (1)

Publication Number Publication Date
CN110025608A true CN110025608A (zh) 2019-07-19

Family

ID=48745439

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910123564.7A Pending CN110025608A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法
CN201380004642.2A Pending CN104136023A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380004642.2A Pending CN104136023A (zh) 2012-01-06 2013-01-04 降低心血管疾病风险的方法

Country Status (9)

Country Link
US (2) US10028926B2 (https=)
EP (2) EP2800564B1 (https=)
JP (2) JP6295205B2 (https=)
CN (2) CN110025608A (https=)
AU (1) AU2013207423B2 (https=)
CA (1) CA2861643C (https=)
HK (1) HK1201452A1 (https=)
MX (1) MX367352B (https=)
WO (1) WO2013103842A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2016077832A2 (en) 2014-11-14 2016-05-19 Gemphire Therapeutics Inc. PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
RU2022102472A (ru) 2015-03-13 2022-03-15 Эсперион Терапеутикс, Инк. Фиксированные комбинации и составы, содержащие etc-1002 и эзетимиб, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
AU2016348638A1 (en) * 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
CN108697677A (zh) * 2016-02-26 2018-10-23 燿石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
WO2018148417A1 (en) * 2017-02-08 2018-08-16 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
TW201906599A (zh) * 2017-05-11 2019-02-16 美商珍費爾醫療公司 吉卡賓組成物及其使用方法
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN112437766A (zh) 2019-06-21 2021-03-02 艾斯柏伦治疗公司 制备贝派地酸及其组合物的方法
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030704A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Statin-carboxyalkylether combinations
CN1100747C (zh) * 1995-03-24 2003-02-05 沃尼尔·朗伯公司 含有末端羧酸基或四唑基的二烃基醚
CN101522623A (zh) * 2006-08-03 2009-09-02 塔夫茨大学信托人 无潮红烟酸类似物和其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
MXPA01009893A (es) 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
IL155215A0 (en) 2000-10-11 2003-11-23 Esperion Therapeutics Inc Ether compounds and compositions for cholesterol management and related uses
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1100747C (zh) * 1995-03-24 2003-02-05 沃尼尔·朗伯公司 含有末端羧酸基或四唑基的二烃基醚
WO1999030704A1 (en) * 1997-12-12 1999-06-24 Warner-Lambert Company Statin-carboxyalkylether combinations
CN101522623A (zh) * 2006-08-03 2009-09-02 塔夫茨大学信托人 无潮红烟酸类似物和其使用方法

Also Published As

Publication number Publication date
CA2861643C (en) 2020-10-06
WO2013103842A1 (en) 2013-07-11
US20180303779A1 (en) 2018-10-25
CA2861643A1 (en) 2013-07-11
EP2800564A1 (en) 2014-11-12
MX367352B (es) 2019-08-16
JP2018104452A (ja) 2018-07-05
EP2800564B1 (en) 2020-05-06
HK1201452A1 (en) 2015-09-04
EP3735967A1 (en) 2020-11-11
US10709678B2 (en) 2020-07-14
CN104136023A (zh) 2014-11-05
MX2014008180A (es) 2014-10-14
US10028926B2 (en) 2018-07-24
AU2013207423A1 (en) 2014-07-24
JP2015503588A (ja) 2015-02-02
AU2013207423B2 (en) 2017-10-12
US20150005386A1 (en) 2015-01-01
JP6295205B2 (ja) 2018-03-14
EP2800564A4 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
CN110025608A (zh) 降低心血管疾病风险的方法
WO2013136277A1 (en) Pharmaceutical compositions for treatment of cardiovascular diseases
ES2752039T3 (es) Agente terapéutico para la dislipidemia
KR20100106958A (ko) 신장 보호제로서 중쇄 길이 지방산 및 글리세라이드
MX2014009640A (es) Metodos de tratamientos de fibrosis.
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
WO2019178023A1 (en) Methods of Treating or Preventing Acute Respiratory Distress Syndrome
JP2009540003A (ja) Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US11602510B2 (en) Agent for use in the treatment of dyslipidemia
HK1250484A1 (zh) 用於治疗胰腺炎的吉卡宾和衍生物
HK40007806A (en) Methods of reducing risk of cardiovascular disease
CN104053441B (zh) 用于预防或治疗高脂血症的药物组合物
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
Fukami et al. PS-BPB03-5: DEVELOPMENT OF A THERAPEUTIC VACCINE FOR DYSLIPIDEMIA AND RELATED DISEASES TARGETING ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3).
CN102416015A (zh) 一种含他汀类药物的组合物及其用途
CN104869988B (zh) 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在治疗动脉粥样硬化中的用途
Genest 75 Secondary prevention strategies post myocardial infarction
HK1219662B (zh) 血脂异常症治疗剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007806

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190719